Kazaa

Kazia Therapeutics is an oncology-focused drug development company based in Sydney, Australia, specializing in therapies for brain cancer and other solid tumors. The company's lead program is paxalisib, a brain-penetrant small molecule inhibitor of the PI3K / Akt / mTOR pathway, which is currently being evaluated in the GBM AGILE pivotal Phase 3 study for glioblastoma. Paxalisib was originally licensed from Genentech and has received Orphan Drug and Fast Track designations from the FDA. Additionally, Kazia is developing EVT801, a selective VEGFR3 inhibitor licensed from Evotec, aimed at treating advanced solid tumors by inhibiting lymphangiogenesis. The company operates a virtual business model, leveraging partnerships with global research institutions and pharmaceutical companies to advance its clinical pipeline.